Talazoparib capsules | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Talzenna
Company
Pfizer Europe MA EEIG (EU authorization holder)
Medicine type
Chemical medicine
Therapeutic area
Oncology
Indications recorded in the public source
EU: Used alone for adults with germline BRCA1/2-mutated, HER2-negative locally advanced or metastatic breast cancer after an anthracycline and/or taxane unless unsuitable; hormone receptor-positive disease also requires prior endocrine therapy or unsuitability. With enzalutamide for adults with metastatic castration-resistant prostate cancer when chemotherapy is not clinically indicated.
Indication source and scope
EU SmPC accessed 2026-11-02; current linked revision. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions